Effect of I,25-dihydroxycholecalciferol in renal osteodystrophy.
A 23-year-old man with medullary cystic disease had been undergoing hemodialysis for 5 years and had become confined to a wheelchair because of renal osteodystrophy. He was treated with 125-dihydroxycholecalciferol, 2.0 mug (later 1.0 mug) three times a week, administered by way of the venous end of the dialysis machine. Within 1 month bone pain lessened and his ability to stand and walk improved. By 3 months he was walking short distances and by 5 months, long distances. Calcium balance was near zero before treatment and was strongly positive during treatment. Bone mineral content in the lower femur, measured by photon absorptiometry, increased at a rate of 32.2% per year. In contrast, 26 other patients on long-term hemodialysis had a mean loss of bone mineral content of 14.0% per year. Radiographs taken during treatment showed a decrease in subperiosteal bone resorption and healing of a pseudofracture. A significant decrease in the mean serum alkaline phosphatase value was noted during treatment, but no significant changes in mean serum calcium or phosphorus values were seen.
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D000576:Americium; D001862:Bone Resorption / Q000187:drug effects; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000378:metabolism; D002118:Calcium / Q000032:analysis / Q000097:blood / Q000378:metabolism; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy* / Q000378:metabolism; D004100:Dihydroxycholecalciferols / Q000627:therapeutic use*; D004341:Drug Evaluation; D005243:Feces / Q000032:analysis; D005269:Femur / Q000378:metabolism; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D008297:Male; D010758:Phosphorus / Q000097:blood; D011859:Radiography; D006435:Renal Dialysis
D004100:Dihydroxycholecalciferols; D006887:Hydroxycholecalciferols; D010758:Phosphorus; D000469:Alkaline Phosphatase; D002118:Calcium; D000576:Americium